** Shares of cancer drug developer iTeos Therapeutics ITOS.O rise 13.6% to $7.86
** ITOS and partner GSK GSK.L say they have terminated development of their experimental lung cancer therapy after its failure to significantly improve progression-free survival in two mid-stage trials
** ITOS says it has initiated a review of strategic alternatives to conserve cash
** "As most investors have already thrown in the towel on TIGIT, the decision to terminate the partnership is viewed as a relief to preserve resources for its Ph 1-stage pipeline" - J.P.Morgan analyst Brian Cheng
** The discontinued drug belongs to a class of treatments focused on the TIGIT receptor that has fallen out of favor in recent years after a spate of clinical setbacks due to low efficacy
** As of last close, ITOS up 4.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。